Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China phase IV study of venetoclax + azacitidine in newly diagnosed AML patients unfit for intensive chemotherapy
CTR20212326Phase 4Active
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of venetoclax, azacitidine in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Jan 2022; status: active.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20212326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212326.